Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Nordnet: Monthly statistics October

In October, Nordnet’s customers made 4,591,700 trades in listed financial instruments, which corresponds to 199,700 trades per day. The number of new customers in October amounted to 3,500 and the number of new customers in 2024 is 190,400. The total number of customers at the end of October was 2,053,300. Please note that the net increase of 3,500 customers from September to October includes a reduction of 22,800 customers connected to the sale of Nordnet’s unsecured lending portfolio to Ikano Bank on October 1. The underlying customer growth for October is thus 26,300 customers. Net savings

ExpreS2ion CEO talking to BioStock about partnering efforts at BIO-Europe

Heading towards phase I studies with breast cancer vaccine candidate ES2B-C001, ExpreS2ion Biotech is actively looking for partners. Also, having a well-validated platform, the company recently announced signing a term sheet with Serum Institute of India regarding a malaria vaccine. BioStock talked to CEO Bent U. Frandsen about this at the partnering conference BIO-Europe.See the full interview at biostock.se : https://www.biostock.se/2024/11/expres2ion-ceo-talking-about-partnering-efforts-at-bio-europe/ This is a press release from BioStock - Connecting

Inify Laboratories enter a research partnership with the Department of Molecular Medicine and Surgery at Karolinska Institutet aiming to advance precision diagnostics within prostate cancer

STOCKHOLM – November 05, 2024 - Inify Laboratories, a unique laboratory service that provides cancer diagnostics within pathology, is proud to announce a partnership with the ProMort research team at Karolinska Institutet, aimed at transforming prostate cancer diagnostics. The primary objective of this collaboration is to improve the precision of prostate cancer diagnosis through AI-driven image analysis.“When our ProMort team started the discussions with Inify, we quickly realized the power of their organization and technology. A collaboration has great potential to further advance the

Alight acquires 11 MW solar park from Soltech

Stockholm, Sweden, November 05, 2024 — Alight, a leading solar developer and independent power producer, is pleased to announce that it has acquired a fully operational 11 MW solar PV park located in Falkenberg municipality from Soltech Energy Solutions.Soltech commissioned the Ramsjöholm solar park in September 2024. The company’s strategy regarding solar and battery parks is to develop projects and sell them once commissioned.* In line with its strategy, Solpark Ramsjöholm is now being purchased by Alight. Richard Nicolin, co-founder and Chief Investment Officer of Alight, says: “This

EHAB has entered a letter of intent to divest its shares in Lyvia

Esmaeilzadeh Holding AB ("EHAB") has signed a letter of intent with an international investor regarding a sale of EHAB's shares in Lyvia Group AB (publ). The sale would address the maturity of EHAB's outstanding bond loan. The transaction is contingent upon a final agreement being reached and customary due diligence. EHAB will disclose additional information in connection with entering into a binding share sale and purchase agreement regarding the transaction. For further information, please contact:Mikael Ericson, CEOmikael.ericson@ehab.group For press related enquires,

Repurchases of shares during week 44, 2024

Between 25 October and 1 November 2024 Attendo AB (LEI code 549300KEJDL2FNITUW65) (“Attendo”) has repurchased in total 255,428 own shares (ISIN: SE0007666110) as part of the repurchase program initiated by the Board.The repurchases form part of the repurchase program of a maximum of 16,138,659 own shares for a total maximum amount of SEK 150,000,000 that Attendo announced on 24 October 2024. The repurchase program, which runs between 25 October 2024 and 6 February 2025, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 and the Commission Delegated

Nordic Mining ASA (EN Expand:NOM): Interim report per 30 September 2024

Please find enclosed Nordic Mining’s interim report and company presentation for the third quarter of 2024. The interim report and company update will be presented digitally today, Tuesday 5 November 2024 at 10.00 (CET). The presentation and Q&A session will be held in English and transferred via webcast. You will have the opportunity to post questions online throughout the webcast session. The webcast will be available on: https://channel.royalcast.com/landingpage/hegnarmedia/20241105_5/ Summary of important events in the third quarter of 2024: · The Company reported NOK 278.3

Peptonic Medical strengthens U.S. market presence with full-scale launch of VagiVital

Peptonic Medical AB (publ) ("Peptonic") is taking a crucial step to establish its VagiVital brand in the U.S. market and drive sales growth of its intimate self-care products. This initiative marks a significant milestone for Peptonic, as the company now assumes full control over brand development, marketing, and sales in the U.S. for the first time. Until now, Peptonic's products have primarily been sold through partners under private labels. With this strategic initiative, Peptonic is positioning itself for a dynamic new phase of growth in the world’s largest healthcare market.Over the

Composition of Faron Pharmaceutical’s Shareholders’ Nomination Board

(“Faron” or “the Company”)    Composition of Faron Pharmaceutical’s Shareholders’ Nomination Board   Company Announcement, 5 November 2024   TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that the following members have been appointed by a meeting of the Company's five largest shareholders to Faron Pharmaceuticals Oy’s Shareholders' Nomination Board:   · Timo Syrjälä, representing himself (Chair) · Erkka Kohonen,

Solteq Plc’s Financial Reporting and Annual General Meeting in 2025

Stock Exchange BulletinFinancial CalendarNovember 5, 2024, at 9:00 a.m.Solteq Plc publishes the following financial reports during 2025: Financial Statements Bulletin 2024 – February 13, 2025, at 08:00 a.m. EETInterim Report 1–3/2025 – April 29, 2025, at 08:00 a.m. EETHalf-Year Report  1–6/2025 – August 21, 2025, at 08:00 a.m. EETInterim Report 1–9/2025 – October 29, 2025, at 08:00 a.m. EET The 2024 Annual Report, including the Report of the Board of Directors and Financial Statements, will be published on Solteq’s website by March 5, 2025.  The Annual General Meeting

Corem divests in Sigtuna and Stockholm for SEK 100 million

In two separate deals, Corem has signed an agreement for the sale of three properties in Sigtuna and a site leasehold in Stockholm for a total underlying property value of SEK 100 million, which is in line with book value.   In Sigtuna, the properties Broby 11:6, Broby 12:6 and Broby 12:9 are divested, and in Stockholm the site leasehold to Domnarvet 11, located in the Lunda industrial area, is divested. The properties mainly consist of areas for warehouses and offices with a total lettable area of approximately 7,160 square meters and a total rental value of SEK 9.4 million.

Peab builds homes in Helsinki

Peab has been commissioned to build two apartment buildings in Oulunkylä in Helsinki. The customer is the City of Helsinki and the contract is worth EUR 13 million, around SEK 151 million.The project comprises construction of two apartment buildings with a total of 78 apartments and two commercial spaces. One building will be five stories high and the other six with a loft for residents. In addition, two parking areas with protection will be built. “This project will be a great continuation of our collaboration with the City of Helsinki with whom we currently have six ongoing joint

Circle BidCo announces final outcome of the offer to the shareholders of Concentric

This announcement is not an offer, whether directly or indirectly, in Australia, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to legislation and regulations in such relevant jurisdiction would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled “Important information” at the end of this announcement and in

Gripen E makes its debut in multinational military exercise

Saab’s fighter jet is a highlight at CRUZEX 2024, the largest multinational operational training exercise in Latin America, organised by the Brazilian Air Force (FAB).Over two thousand military personnel from Brazil and 15 other nations from across Latin America, Africa, Europe and the United States are gathered for one of the largest operational air exercises in the Southern Hemisphere, CRUZEX 2024. Held from 3 to 15 November at the Natal Air Base in Rio Grande do Norte, Brazil, the exercise features over 100 combat aircraft. The main highlight of this edition is the debut of the F-39E

Innovative Capitainer®SEP10 Revolutionizes Blood Plasma Sampling

Capitainer, a leading Swedish MedTech company specializing in advanced self-sampling solutions, has announced the launch of a new sampling card designed for collecting separated blood from a finger prick. Capitainer®SEP10 generates a plasma-like sample without the need for a centrifuge, providing at-home sampling capabilities to areas previously not feasible, making it ideal for testing substances that cannot be measured from a whole blood sample. Capitainer's innovative sampling card Capitainer®SEP10 is developed for collection of blood where the cells are separated from the

Capsol Technologies ASA - Q3 2024: Strengthened CCS business case for emitters drives demand growth

Capsol Technologies ASA, a provider of carbon capture technology to large emitters, today announced its results for Q3 2024.Steady demand growth · Revenues up 80% to NOK 21.6 million, compared to same period in 2023. · Mature project pipeline up ~60% to 15 million tons CO2, representing potential pre-tax profits of more than NOK 1.2 billion. · Growing traction in cement sector with award of feasibility study from cement producer in Germany and CapsolGo® campaigns with SCHWENK, a leading European cement producer.   Lower cost solution yields attractive returns for emitters

Vestas – Interim Financial Report, Third Quarter 2024

Vestas Wind Systems A/S, Aarhus, 05 November 2024Company Announcement no. 16/2024 Summary: Quarterly revenue of EUR 5.2bn with an EBIT margin before special items of 4.5 percent. Order intake of 4.4 GW and combined order backlog of EUR 63.4bn. Revenue and EBIT margin guidance maintained with adjustments to Service EBIT and total investments. Lower end of the guidance range now more likely for the Group EBIT margin. In the third quarter of 2024, Vestas generated revenue of EUR 5,177m – an increase of 18.9 percent compared to the year-earlier period. EBIT before special items amounted

EQT X, THROUGH OAK BIDCO S.À R.L., HAS SECURED AN OWNERSHIP OF 72.5% OF THE VOTES IN OEM INTERNATIONAL AKTIEBOLAG (PUBL) AND ANNOUNCES A CASH OFFER TO ALL SHAREHOLDERS

This announcement is not an offer, whether directly or indirectly, in Australia, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to legislation and regulations in such relevant jurisdiction would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled “Important information” at the end of this announcement and in

Raisio plc’s Interim Report January-September 2024

Raisio Plc’s Interim Report, November 5th, 2024 at 8.30 a.m. Finnish timeNet sales grew driven by sales volumes   FINANCIAL DEVELOPMENT IN BRIEF   JULY–SEPTEMBER 2024, CONTINUING OPERATIONS • The Group's net sales totalled EUR 59.1 (56.1) million, which signified a growth of 5.4%.• Comparable EBITDA was EUR 9.0** (9.9) million, which accounted for 15.2 (17.6) per cent of net sales.• EBITDA was EUR 8.1* (9.6*) million, which accounted for 13.7 (17.0) per cent of net sales.• Comparable EBIT was EUR 6.5** (7.4) million, accounting for 11.1 (13.1) per cent of net sales.•

There are no items matching the current filter
There are no more items matching the current filter
Back to top